Evidence-Based Nccn ipi dlbcl Scoring

Recent Journal Updates

Alzheimers & DementiaJun 8, 2026

Urban greenspace and dementia: Measures, mechanisms, and methodological guidance

Clinical Context

We think this has broad domain relevance to NCCNIPIDLBCL.

DiabetologiaJun 8, 2026

Genetics of MASLD: a diabetes perspective

Clinical Context

We think this has broad domain relevance to NCCNIPIDLBCL.

DiabetologiaJun 6, 2026

Plasma small RNA profiling reveals a three-miRNA signature associated with early beta cell dysfunction across glucose tolerance stages

Clinical Context

We think this has broad domain relevance to NCCNIPIDLBCL.

NCCN-IPIEnhanced DLBCL Prognostic Index

Demographics & Serology

Patient Age

LDH Level (Ratio to ULN)

Staging & Status

*Specific sites (Bone Marrow, CNS, Liver/GI tract, Lung) also count toward the extranodal point.

Awaiting Clinical Data

The NCCN-IPI is the current clinical standard for risk-stratifying patients with DLBCL in the modern rituximab era.

Risk Tiers

0-1: Low Risk
2-3: Low-Intermediate
4-5: High-Intermediate
>=6: High Risk

Guidelines & Evidence

Verified

Last Review: 2026

When to Use

Newly diagnosed Diffuse Large B-Cell Lymphoma (DLBCL).

Used prior to the initiation of frontline chemoimmunotherapy (e.g., R-CHOP, Pola-R-CHP) to counsel patients on long-term overall survival expectations.

Helps identify the highest risk cohort (High risk NCCN-IPI) that may be considered for frontline clinical trials or CAR-T evaluations if relapse occurs.

Related Scores in Practice

In clinical practice, this assessment is frequently evaluated alongside other validated measures. Depending on the patient's presentation and specific diagnostic requirements, you may also need to utilize the CNS-IPI, IPSID / Lugano Classification or the FLIPI-2 to formulate a comprehensive care plan.

Last Comprehensive Review: 2026

Recent Journal Updates

NCCN-IPI (DLBCL)

Demographics & Serology

Staging & Status

When to Use

When to Use

Related Scores in Practice

Related Oncology Tools

Recent Journal Updates

NCCN-IPI (DLBCL)

Demographics & Serology

Staging & Status

When to Use

When to Use

Related Scores in Practice

Related Oncology Tools